Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program-Reference-Cited by-同舟云学术

Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Published:2021-08-18 Issue:5 Volume:22 Page:693-707
ISSN:1175-0561
Container-title:American Journal of Clinical Dermatology
language:en
Short-container-title:Am J Clin Dermatol

Author:

Simpson Eric L.,Silverberg Jonathan I.,Nosbaum Audrey,Winthrop Kevin L.,Guttman-Yassky Emma,Hoffmeister Karin M.,Egeberg Alexander,Valdez Hernan,Zhang Min,Farooqui Saleem A.,Romero William,Thorpe Andrew J.,Rojo Ricardo,Johnson Susan^ORCID

Funder

Pfizer Inc.

Publisher

Springer Science and Business Media LLC

Subject

Dermatology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s40257-021-00618-3.pdf

Reference45 articles.

1. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10-22 e2.

2. Newton L, DeLozier AM, Griffiths PC, Hill JN, Hudgens S, Symonds T, et al. Exploring content and psychometric validity of newly developed assessment tools for itch and skin pain in atopic dermatitis. J Patient Rep Outcomes. 2019;3(1):42.

3. Silverberg JI, Gelfand JM, Margolis DJ, Boguniewicz M, Fonacier L, Grayson MH, et al. Pain is a common and burdensome symptom of atopic dermatitis in United States Adults. J Allergy Clin Immunol Pract. 2019;7(8):2699-706.e7.